Results 171 to 178 of about 18,115 (178)

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

Annals of Oncology, 2019
K Akiyoshi, M Asayama, T Denda
exaly  

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma

European Journal of Cancer, 2018
Nicolas Penel, Jean-Yves Blay, Christine Chevreau   +2 more
exaly  

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

Annals of Oncology, 2013
Gunnar Folprecht, C H Kohne, C H Kohne
exaly  

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer

Cancer Letters, 2017
Qi-Wei Jiang, Zhe-Sheng Chen
exaly  

Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging

Cancer Letters, 2019
Yang Du, Xu Zhu
exaly  

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Annals of Oncology, 2016
Michael Heinrich, A J Wagner, J T Yap
exaly  

Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer

Cancer Letters, 2019
De-Shen Wang, Amal Kaddoumi, Ambudkar Sv   +2 more
exaly  

A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis

Clinical Colorectal Cancer, 2018
Kelvin Chan, Yoo‐Joung Ko
exaly